Jacob Bell
Senior Reporter | @realjacobbellJacob graduated from the University of Maryland with degrees in journalism and biology. He's previously reported on M&A at TheDeal, politics at McClatchy DC and education research at Education Week. His main interests include RuPaul's Drag Race, anything from the McDonalds menu and strong shoe game. He has loud opinions about avocado toast and Vine ending.
1549 articles by Jacob Bell
-
Bristol Myers cell therapy wins first-of-its-kind approval
March 15, 2024 -
After surprise trial failure, ALS doctors brace for one less treatment option
March 12, 2024 -
Amylyx CEOs look for a path forward following major setback
March 11, 2024 -
Amylyx ALS drug fails crucial study, putting company’s future in doubt
March 8, 2024 -
NodThera says inflammation drug has positive effect in Parkinson’s
March 7, 2024 -
Gilead bets on ‘trispecifics’ in latest cancer drug deal
March 6, 2024 -
Bayer isn’t splitting up, for now
March 5, 2024 -
Cure Ventures backs a cell therapy startup targeting Parkinson’s
Feb. 29, 2024 -
Incannex says psilocybin therapy lowered anxiety in small study
Feb. 28, 2024 -
NGM to go private through deal with investment firm
Feb. 26, 2024 -
AbbVie’s Cerevel deal hits an uncommon roadblock
Feb. 20, 2024 -
Intellia, ReCode partner on genetic medicines for cystic fibrosis
Feb. 15, 2024 -
Biogen has a fuzzy line of sight on prized Alzheimer’s drug
Feb. 13, 2024 -
Takeda speeds narcolepsy drug to late-stage testing
Feb. 9, 2024 -
Neurona raises another $120M for brain disease cell therapies
Feb. 8, 2024 -
Eisai falls behind on Leqembi patient goal
Feb. 6, 2024 -
J&J says top drug prospect works across autoimmune disorders
Feb. 5, 2024 -
Biogen quits Aduhelm, handing back rights to original developer
Jan. 31, 2024 -
Karuna, Cerevel might be just the start of psychiatry drug M&A
Jan. 22, 2024 -
Biogen CEO sees progress in launch of Alzheimer’s drug Leqembi
Jan. 8, 2024 -
An unusual drugmaker raises north of $100M for ecstasy-based PTSD therapy
Jan. 5, 2024 -
10 clinical trials to watch in the first half of 2024
Jan. 2, 2024 -
Clene says its ALS drug data is not yet enough for FDA
Dec. 21, 2023 -
As ALS research booms, one treatment center finds itself in the spotlight
Dec. 20, 2023 -
Investors still aren’t sold on UniQure’s gene therapy for Huntington’s
Dec. 19, 2023